Contents
Clinical research in Montana specializes in the coordination and management of Phase 1 to Phase 4 trials. Trained professionals combine years of experience and data to provide new treatments, drugs, and devices that can boost clinical practice.
Volunteers such as yourself are always welcome. With your help, experts can shape the very future of disease treatment. We can introduce you to clinical trials in your local area.
Clinical Trials For Disease Areas in Montana
Montana is one of the most rural areas in the United States. About 43.6% of its population lives in rural regions. Compared to regions with bigger cities, Montana doesn’t have a broad range of clinical research trials. But, those that are available provide access to quality care and use the latest technology.
Since 2004, roughly 1,200 clinical trials have been done in Montana. Many of the state’s trials focus on environmental health. Others try to address the unique challenges of rural health disparities and access to healthcare in remote areas.
For example, the Montana State Univerisity is actively engaged in the study of virology, microbiology, immunology, and molecular biology. Each sector has something unique to offer for medical advancements.
Want to participate in cutting-edge medical research? Browse our list of available trials in your local area.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Community Hospital of Anaconda, Anaconda, Montana +11 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Saint Vincent Healthcare, Billings, Montana
Saint Vincent Frontier Cancer Center, Billings, Montana
Bozeman Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Saint Peter's Community Hospital, Helena, Montana
Kalispell Regional Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Hospital, Missoula, Montana
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana +11 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Saint Vincent Healthcare, Billings, Montana
Saint Vincent Frontier Cancer Center, Billings, Montana
Bozeman Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Saint Peter's Community Hospital, Helena, Montana
Kalispell Regional Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Hospital, Missoula, Montana
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana +10 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Hi-Line Sletten Cancer Center, Havre, Montana
Saint Peter's Community Hospital, Helena, Montana
Logan Health Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Center, Missoula, Montana
Conditions: Previously Treated Non-Small Cell Lung Cancer
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Community Hospital of Anaconda, Anaconda, Montana +7 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Kalispell Regional Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Center, Missoula, Montana
Conditions: Multiple Myeloma
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana +10 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Saint Vincent Healthcare, Billings, Montana
Saint Vincent Frontier Cancer Center, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Kalispell Regional Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Center, Missoula, Montana
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Recruiting
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach... Read More
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Community Hospital of Anaconda, Anaconda, Montana +7 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Bozeman Deaconess Hospital, Bozeman, Montana
Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Kalispell Regional Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Hospital, Missoula, Montana
Conditions: Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recruiting
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers. Read Less
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
03/28/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana +8 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Hi-Line Sletten Cancer Center, Havre, Montana
Logan Health Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Center, Missoula, Montana
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Recruiting
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by k... Read More
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana +10 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Saint Vincent Frontier Cancer Center, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Hi-Line Sletten Cancer Center, Havre, Montana
Logan Health Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Center, Missoula, Montana
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Community Hospital of Anaconda, Anaconda, Montana +7 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Bozeman Deaconess Hospital, Bozeman, Montana
Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Kalispell Regional Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Hospital, Missoula, Montana
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana +5 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Logan Health Medical Center, Kalispell, Montana
Community Medical Center, Missoula, Montana
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Paid Clinical Trials in Montana
Every treatment, medical device, and therapy is carefully tested before it becomes available to the public. Paid clinical trials provide patients with the perfect opportunity to earn something in exchange for participating in trials.
MT paid clinical trials provide different forms of compensation. You can get paid or receive non-monetary benefits. Like free medical care, or compensation for traveling and accommodation expenses.
Clinical Trials For Health Volunteers in Montana
Research teams in Montana need you to make a lasting impact. By taking part in a clinical trial, you are not just a volunteer, you are a pioneer who can help take healthcare to a completely different level.
Take a look at the trial list below to find the one that suits you best.
Integrated Cancer Repository for Cancer Research
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies. Read Less
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: Bozeman Health Deaconess Hospital, Bozeman, Montana +1 locations
Bozeman Health Deaconess Hospital, Bozeman, Montana
Logan Health, Kalispell, Montana
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Recruiting
Background:
Infections in the lower respiratory tract (lungs) are the leading cause of death from infectious disease worldwide. This was true even before the COVID-19 pandemic. Respiratory viruses are still a major health threat. Many of these viruses infect people by penetrating the thin skin that lines the nose. These viruses can also spread easily to other people when they multiply in the tissues that line the nose. Researchers want to learn more about what these viruses do inside the nose,... Read More
Background:
Infections in the lower respiratory tract (lungs) are the leading cause of death from infectious disease worldwide. This was true even before the COVID-19 pandemic. Respiratory viruses are still a major health threat. Many of these viruses infect people by penetrating the thin skin that lines the nose. These viruses can also spread easily to other people when they multiply in the tissues that line the nose. Researchers want to learn more about what these viruses do inside the nose, how they get from the nose to the lungs, and how they spread from person to person.
Objective:
To collect cell samples from inside the noses of healthy people. These cells will be stored for use in future research on respiratory diseases.
Eligibility:
Healthy volunteers aged 18 years and older.
Design:
Most participants will have 1 visit on 1 day. They will be asked questions. Those who have a runny nose, coughing, congestion, or fever will be asked to wait up to 21 days before participating.
Participants will be given a slender swab with small bristles at the end. They will rub the inside of their nose with the swab. A clinic staff member will be present to help, if needed.
Participants will provide their name, age, and sex. This information will be encoded so that only certain researchers will know the participants identities.
Participants will not be contacted again.... Read Less
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/09/2025
Locations: Rocky Mountain Laboratories, Hamilton, Montana
Rocky Mountain Laboratories, Hamilton, Montana
Conditions: Healthy
Medical Discoveries and Innovation in Montana
Many medical discoveries and achievements come from Montana research institutions. They reflect the expertise of medical specialists over the years. These include:
- Advancements in Rural Healthcare Delivery: The Montana AHEC Program has been critical in developing new and improved approaches to deliver quality care to underserved and rural areas. Their initiatives improved access to healthcare services across all MT communities.
- Traumatic Brain Injury Research: Clinical studies in the area made notable contributions to the treatment of traumatic brain injuries. Each trial has helped improve interventions and protocols for patients with severe brain injuries.
- Environmental Health Research: The state of Montana has the latest biomedical research equipment. The University of Montana has done numerous studies about the impact of environmental factors on overall health. The data collected can help improve available treatments for various diseases.
Why Montana Is A Great Place For Clinical Research
Montana clinical research can benefit from volunteers of different ethnic and racial backgrounds. Here, 85.5% of its population is White, 6% is American Indian, 4.3% is Hispanic, 2.6% is Multiracial, 1% is Asian, and 0.6% is Black.